Physician

Surrinder Paul Dang, M.D.

According to 2025 Medicare claims, Surrinder Dang, M.D. (NPI: 1699755116) practices hematology/oncology in the Huntsville, AL market, with the plurality of this provider's patient population coming from Madison, AL. This provider's primary affiliated billing organization is ONCOLOGY SPECIALTIES, P.C. (NPI: 1669425716; TIN: 630897317) and primary practice location at 35801-3495.

Dang's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 935 traditional Medicare patients, billed 222,554 HCPCS/CPT codes, and received $4,054,974 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,416 prescription claims across 364 beneficiaries totaling $7,650,191 in drug costs, led by Verzenio (Abemaciclib). DME data shows 31 claims. Open Payments data shows 72 records totaling $1,981. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $2,463,348 to $7,650,191. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $29,105 to $1,051.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,188	440,157	$4,693,726
2016	1,181	499,654	$4,662,779
2017	1,029	420,747	$4,559,119
2018	1,058	320,778	$4,188,746
2019	1,021	275,041	$3,379,384
2020	973	283,926	$4,030,207
2021	972	269,363	$4,021,809
2022	897	245,256	$3,687,236
2023	902	224,348	$3,711,946
2024	935	222,554	$4,054,974

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	311	2,858	$2,463,348
2016	347	2,783	$2,930,576
2017	321	2,747	$3,426,977
2018	336	2,684	$3,875,514
2019	313	2,235	$3,328,942
2020	310	2,303	$3,548,497
2021	316	2,097	$3,385,667
2022	330	2,089	$4,175,072
2023	336	2,204	$6,139,412
2024	364	2,416	$7,650,191

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	42	448	$55,582
2016	35	271	$23,190
2017	12	281	$52,773
2018	N/R	199	$45,999
2019	N/R	87	$4,632
2020	N/R	130	$57,415
2021	N/R	N/R	N/R
2022	N/R	22	$1,855
2023	N/R	N/R	N/R
2024	N/R	31	$628

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	434	767	$89
82728	Ferritin (blood protein) level	325	473	$13
80053	Blood test, comprehensive group of blood chemicals	754	1,986	$10
36415	Insertion of needle into vein for collection of blood sample	740	1,694	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	755	2,031	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Verzenio	Abemaciclib	63	1,764	$903,897
Jakafi	Ruxolitinib Phosphate	36	1,080	$584,408
Imbruvica	Ibrutinib	38	1,064	$572,863
Revlimid	Lenalidomide	29	798	$538,434
Xtandi	Enzalutamide	39	1,170	$472,540

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	15	$414
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	16	$213

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	72	$1,981	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Surrinder Paul Dang, M.D.?

Tedicare shows public-source Medicare data for Surrinder Paul Dang, M.D. (NPI 1699755116), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Surrinder Paul Dang, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Surrinder Paul Dang, M.D.?

Surrinder Paul Dang, M.D. is linked to ONCOLOGY SPECIALTIES, P.C. (billing NPI 1669425716) in the available physician profile data.

Does Surrinder Paul Dang, M.D. have Open Payments data?

Surrinder Paul Dang, M.D. has 72 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.